AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
Spirovant has announced the commencement of its Phase I/II study with the first patient receiving a dose of SP-101 to treat ...
The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback